BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 22484209)

  • 21. Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.
    Noguchi K; Kawahara H; Kaji A; Katayama K; Mitsuhashi J; Sugimoto Y
    Cancer Sci; 2009 Sep; 100(9):1701-7. PubMed ID: 19493273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
    Minocha M; Khurana V; Qin B; Pal D; Mitra AK
    Int J Pharm; 2012 Sep; 434(1-2):306-14. PubMed ID: 22633931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sipholenol A, a marine-derived sipholane triterpene, potently reverses P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells.
    Shi Z; Jain S; Kim IW; Peng XX; Abraham I; Youssef DT; Fu LW; El Sayed K; Ambudkar SV; Chen ZS
    Cancer Sci; 2007 Sep; 98(9):1373-80. PubMed ID: 17640301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel flavonoid from Fissistigma cupreonitens, 5‑hydroxy‑7,8‑dimethoxyflavanone, competitively inhibited the efflux function of human P-glycoprotein and reversed cancer multi-drug resistance.
    Teng YN; Lin KI; Lin YC; Thang TD; Lan YH; Hung CC
    Phytomedicine; 2021 May; 85():153528. PubMed ID: 33735724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
    Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
    Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line.
    Wen J; Zheng B; Hu Y; Zhang X; Yang H; Luo KJ; Zhang X; Li YF; Fu JH
    Oncol Rep; 2009 Jul; 22(1):65-71. PubMed ID: 19513506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding and inhibition of drug transport proteins by heparin: a potential drug transporter modulator capable of reducing multidrug resistance in human cancer cells.
    Chen Y; Scully M; Petralia G; Kakkar A
    Cancer Biol Ther; 2014 Jan; 15(1):135-45. PubMed ID: 24253450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.
    Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW
    Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Function and expression of ATP-binding cassette transporters in cultured human Y79 retinoblastoma cells.
    Ishikawa Y; Nagai J; Okada Y; Sato K; Yumoto R; Takano M
    Biol Pharm Bull; 2010; 33(3):504-11. PubMed ID: 20190417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance.
    van Oosterwijk JG; Herpers B; Meijer D; Briaire-de Bruijn IH; Cleton-Jansen AM; Gelderblom H; van de Water B; Bovée JV
    Ann Oncol; 2012 Jun; 23(6):1617-26. PubMed ID: 22112972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
    Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
    Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents.
    Sampson A; Peterson BG; Tan KW; Iram SH
    Biomed Pharmacother; 2019 Oct; 118():109289. PubMed ID: 31401398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tenulin and isotenulin inhibit P-glycoprotein function and overcome multidrug resistance in cancer cells.
    Chang YT; Wang CCN; Wang JY; Lee TE; Cheng YY; Morris-Natschke SL; Lee KH; Hung CC
    Phytomedicine; 2019 Feb; 53():252-262. PubMed ID: 30668405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
    David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
    Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
    To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
    J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
    Grundy M; Seedhouse C; Russell NH; Pallis M
    BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of 7-
    Chen Y; Li X; Shi L; Ma P; Wang W; Wu N; Gan Y; Han X; Huang S; Kang X; Liu S; Zhen Y
    Aging (Albany NY); 2022 Sep; 14(17):7156-7169. PubMed ID: 36107024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein kinase Cα protects against multidrug resistance in human colon cancer cells.
    Lee SK; Shehzad A; Jung JC; Sonn JK; Lee JT; Park JW; Lee YS
    Mol Cells; 2012 Jul; 34(1):61-9. PubMed ID: 22639047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines.
    Levi M; Salaroli R; Parenti F; De Maria R; Zannoni A; Bernardini C; Gola C; Brocco A; Marangio A; Benazzi C; Muscatello LV; Brunetti B; Forni M; Sarli G
    BMC Vet Res; 2021 Jan; 17(1):30. PubMed ID: 33461558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P.
    Marbeuf-Gueye C; Salerno M; Quidu P; Garnier-Suillerot A
    Eur J Pharmacol; 2000 Mar; 391(3):207-16. PubMed ID: 10729360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.